GILEAD SCIENCES, INC.

GILD 10-Q · Q1 2026
API behind this page

GILD Q1 2026 request

Playground key active
Request URL /api/financials?ticker=GILD&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue (Q) — — —
Show Product Lines breakouts
AmBisome 138 139 -0.7%
AmBisome · Europe 59 67 -11.9%
AmBisome · Rest of World 72 66 +9.1%
AmBisome · US 7 5 +40.0%
Biktarvy 3,361 3,150 +6.7%
Biktarvy · Europe 437 375 +16.5%
Biktarvy · Rest of World 352 301 +16.9%
Biktarvy · US 2,573 2,474 +4.0%
Descovy 807 586 +37.7%
Descovy · Europe 23 21 +9.5%
Descovy · Rest of World 23 27 -14.8%
Descovy · US 761 538 +41.4%
Genvoya 264 364 -27.5%
Genvoya · Europe 33 40 -17.5%
Genvoya · Rest of World 16 19 -15.8%
Genvoya · US 215 305 -29.5%
Livdelzi 133 40 +232.5%
Livdelzi · Europe 18 — —
Livdelzi · US 115 40 +187.5%
Odefsey 221 281 -21.4%
Odefsey · Europe 59 57 +3.5%
Odefsey · Rest of World 9 10 -10.0%
Odefsey · US 153 215 -28.8%
Other 58 70 -17.1%
Other HIV 73 91 -19.8%
Other HIV · Europe 27 31 -12.9%
Other HIV · Rest of World 9 10 -10.0%
Other HIV · US 36 50 -28.0%
Other Liver Disease 114 121 -5.8%
Other Liver Disease · Europe 78 76 +2.6%
Other Liver Disease · Rest of World 21 17 +23.5%
Other Liver Disease · US 15 28 -46.4%
Other · Europe 8 9 -11.1%
Other · Rest of World 11 14 -21.4%
Other · US 39 47 -17.0%
Product 6,946 6,613 +5.0%
Product · Europe 1,137 1,073 +6.0%
Product · Rest of World 883 909 -2.9%
Product · US 4,926 4,631 +6.4%
Royalty, contract and other revenues 14 54 -74.1%
Royalty, contract and other revenues · Europe 8 11 -27.3%
Royalty, contract and other revenues · Rest of World 6 6 0.0%
Sofosbuvir/Velpatasvir 283 346 -18.2%
Sofosbuvir/Velpatasvir · Europe 60 80 -25.0%
Sofosbuvir/Velpatasvir · Rest of World 82 99 -17.2%
Sofosbuvir/Velpatasvir · US 141 166 -15.1%
Symtuza - Revenue share 138 114 +21.1%
Symtuza - Revenue share · Europe 28 29 -3.4%
Symtuza - Revenue share · Rest of World 3 3 0.0%
Symtuza - Revenue share · US 107 82 +30.5%
Tecartus 75 78 -3.8%
Tecartus · Europe 37 31 +19.4%
Tecartus · Rest of World 8 8 0.0%
Tecartus · US 30 40 -25.0%
Total Cell Therapy 407 464 -12.3%
Total Cell Therapy · Europe 183 180 +1.7%
Total Cell Therapy · Rest of World 74 84 -11.9%
Total Cell Therapy · US 150 200 -25.0%
Total HIV 5,030 4,587 +9.7%
Total HIV · Europe 607 553 +9.8%
Total HIV · Rest of World 419 370 +13.2%
Total HIV · US 4,004 3,664 +9.3%
Total Liver Disease 767 758 +1.2%
Total Liver Disease · Europe 170 168 +1.2%
Total Liver Disease · Rest of World 235 256 -8.2%
Total Liver Disease · US 362 335 +8.1%
Total Oncology 810 757 +7.0%
Total Oncology · Europe 278 255 +9.0%
Total Oncology · Rest of World 129 121 +6.6%
Total Oncology · US 403 381 +5.8%
Total Other 196 209 -6.2%
Total Other · Europe 67 76 -11.8%
Total Other · Rest of World 83 81 +2.5%
Total Other · US 46 52 -11.5%
Trodelvy 402 293 +37.2%
Trodelvy · Europe 95 75 +26.7%
Trodelvy · Rest of World 54 37 +45.9%
Trodelvy · US 253 181 +39.8%
Veklury 144 302 -52.3%
Veklury · Europe 14 22 -36.4%
Veklury · Rest of World 18 82 -78.0%
Veklury · US 112 199 -43.7%
Vemlidy 237 252 -6.0%
Vemlidy · Europe 13 12 +8.3%
Vemlidy · Rest of World 132 140 -5.7%
Vemlidy · US 91 100 -9.0%
Yescarta 332 386 -14.0%
Yescarta · Europe 146 149 -2.0%
Yescarta · Rest of World 67 77 -13.0%
Yescarta · US 120 160 -25.0%
Yeztugo 166 — —
Yeztugo · Rest of World 7 — —
Yeztugo · US 158 — —
Show Geography breakouts
Europe 1,144 1,084 +5.5%
Rest of World 889 915 -2.8%
US 4,926 4,668 +5.5%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income -24 21 -214.3%
Show — breakouts
Revenue 6,960 6,667 +4.4%
Cost of Revenue (Q) — — —
Show — breakouts
Cost of Revenue 1,445 1,540 -6.2%
Research And Development Expense Excluding Acquired In Process Cost (Q) — — —
Show — breakouts
Research And Development Expense Excluding Acquired In Process Cost 1,372 1,379 -0.5%
Research And Development Asset Acquired Other Than Through Business Combination Written Off (Q) — — —
Show — breakouts
Research And Development Asset Acquired Other Than Through Business Combination Written Off 107 253 -57.7%
Selling, General & Administrative (Q) — — —
Show Business Segments breakouts
Reportable Segment 1,451 1,258 +15.3%
Show — breakouts
Selling, General & Administrative 1,451 1,258 +15.3%
Show Counterparty Name breakouts
Gilead Foundation · Related Party 63 — —
Total Costs & Expenses (Q) — — —
Show — breakouts
Total Costs & Expenses 4,374 4,430 -1.3%
Operating Income (Q) — — —
Show — breakouts
Operating Income 2,586 2,237 +15.6%
Interest Expense (Q) — — —
Show — breakouts
Interest Expense 240 260 -7.7%
Non-Operating Income (Expense) (Q) — — —
Show Equity Components breakouts
Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income -2 — —
Show — breakouts
Non-Operating Income (Expense) -235 328 -171.6%
Income Before Taxes (Q) — — —
Show — breakouts
Income Before Taxes 2,580 1,649 +56.5%
Income Tax Expense (Benefit) (Q) — — —
Show Equity Components breakouts
Income tax (benefit) expense · Reclassification Out Of Accumulated Other Comprehensive Income -3 3 -200.0%
Show — breakouts
Income Tax Expense (Benefit) 559 334 +67.4%
Net Income (Q) — — —
Show Equity Components breakouts
Retained Earnings 2,021 1,315 +53.7%
Show — breakouts
Net Income 2,021 1,315 +53.7%
EPS (Basic) (Q) — — —
Show — breakouts
EPS (Basic) 1.63 1.06 +53.8%
EPS (Diluted) (Q) — — —
Show — breakouts
EPS (Diluted) 1.61 1.04 +54.8%
Wtd Avg Shares (Basic) (Q) — — —
Show — breakouts
Wtd Avg Shares (Basic) 1,242 1,246 -0.3%
Wtd Avg Shares (Diluted) (Q) — — —
Show — breakouts
Wtd Avg Shares (Diluted) 1,254 1,259 -0.4%
Sales & Marketing (Q) — — —
Show Business Segments breakouts
Reportable Segment 898 753 +19.3%
General & Administrative (Q) — — —
Show Business Segments breakouts
Reportable Segment 553 505 +9.5%
Other Non-Operating Income (Expense) (Q) — — —
Show — breakouts
Other Non-Operating Income (Expense) 2 -4 +150.0%
Comprehensive Income (Q) — — —
Show — breakouts
Comprehensive Income 2,060 1,275 +61.6%
Other Comprehensive Income (Q) — — —
Show Equity Components breakouts
Accumulated Other Comprehensive Income 39 -40 +197.5%
Show — breakouts
Other Comprehensive Income 39 -40 +197.5%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) — — —
Show — breakouts
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax 61 -58 +205.2%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) — — —
Show — breakouts
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 7,628 7,926 -3.8%
Marketable Securities (Current) (Q) — — —
Show — breakouts
Marketable Securities (Current) 15 — —
Accounts Receivable (Q) — — —
Show — breakouts
Accounts Receivable 4,741 4,388 +8.0%
Inventory (Q) — — —
Show — breakouts
Inventory 1,914 — —
Show Public Utilities Inventory breakouts
Trodelvy 638 — —
Prepaid Expenses & Other Current Assets (Q) — — —
Show — breakouts
Prepaid Expenses & Other Current Assets 4,342 2,828 +53.5%
Total Current Assets (Q) — — —
Show — breakouts
Total Current Assets 18,641 16,901 +10.3%
Non-Current Assets
Property, Plant & Equipment (Q) — — —
Show — breakouts
Property, Plant & Equipment 5,638 5,421 +4.0%
Marketable Securities (Non-Current) (Q) — — —
Show — breakouts
Marketable Securities (Non-Current) 983 — —
Goodwill (Q) — — —
Show — breakouts
Goodwill 8,314 8,314 0.0%
Deferred Tax Assets (Q) — — —
Show — breakouts
Deferred Tax Assets 1,767 2,572 -31.3%
Other Non-Current Assets (Q) — — —
Show — breakouts
Other Non-Current Assets 4,554 3,871 +17.6%
Total Assets (Q) — — —
Show — breakouts
Total Assets 56,278 56,434 -0.3%
Intangible Assets (Q) — — —
Show — breakouts
Intangible Assets 14,082 16,465 -14.5%
Show Finite Lived Intangible Assets By Major Class breakouts
Hepcludex [Member] 408 494 -17.4%
Intangible asset – axicabtagene ciloleucel 3,881 4,288 -9.5%
Intangible asset – sofosbuvir 2,097 2,797 -25.0%
Other Intangible Assets 400 510 -21.6%
Trodelvy 7,296 8,377 -12.9%
Other Assets
Intangible Assets Net Excluding Goodwill (Q) — — —
Show — breakouts
Intangible Assets Net Excluding Goodwill 16,382 19,355 -15.4%
Current Liabilities
Accounts Payable (Q) — — —
Show — breakouts
Accounts Payable 645 737 -12.5%
Accrued Rebates (Q) — — —
Show — breakouts
Accrued Rebates 4,118 4,185 -1.6%
Debt Current (Q) — — —
Show — breakouts
Debt Current 1,313 2,806 -53.2%
Other Liabilities Current (Q) — — —
Show — breakouts
Other Liabilities Current 3,399 4,615 -26.3%
Total Current Liabilities (Q) — — —
Show — breakouts
Total Current Liabilities 9,476 12,344 -23.2%
Current Portion of Long-Term Debt (Q) — — —
Show — breakouts
Current Portion of Long-Term Debt 1,313 — —
Non-Current Liabilities
Long-Term Debt (Q) — — —
Show — breakouts
Long-Term Debt 20,861 — —
Accrued Income Taxes Noncurrent (Q) — — —
Show — breakouts
Accrued Income Taxes Noncurrent 918 819 +12.1%
Deferred Tax Liabilities (Q) — — —
Show — breakouts
Deferred Tax Liabilities 392 709 -44.7%
Other Non-Current Liabilities (Q) — — —
Show — breakouts
Other Non-Current Liabilities 1,200 1,337 -10.2%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
1.20% Senior Unsecured Notes Due October 2027 · Senior Notes 749 — —
1.65% Senior Unsecured Notes Due October 2030 · Senior Notes 996 — —
2.60% Senior Unsecured Notes Due October 2040 · Senior Notes 990 — —
2.80% Senior Unsecured Notes Due October 2050 · Senior Notes 1,480 — —
2.95% Senior Unsecured Notes Due March 2027 · Senior Notes 1,249 — —
4.00% Senior Unsecured Notes Due September 2036 · Senior Notes 744 — —
4.15% Senior Unsecured Notes Due March 2047 · Senior Notes 1,731 — —
4.50% Senior Unsecured Notes Due February 2045 · Senior Notes 1,736 — —
4.60% Senior Unsecured Notes Due September 2035 · Senior Notes 994 — —
4.75% Senior Unsecured Notes Due March 2046 · Senior Notes 2,225 — —
4.80% Senior Unsecured Notes Due April 2044 · Senior Notes 1,738 — —
4.80% Senior Unsecured Notes Due In November 2029 · Senior Notes 747 — —
5.10% Senior Unsecured Notes Due June 2035 · Senior Notes 992 — —
5.25% Senior Unsecured Notes Due October 2033 · Senior Notes 994 — —
5.50% Senior Unsecured Notes Due November 2054 · Senior Notes 989 — —
5.55% Senior Unsecured Notes Due October 2053 · Senior Notes 989 — —
5.60% Senior Unsecured Notes Due November 2064 · Senior Notes 739 — —
5.65% Senior Unsecured Notes Due December 2041 · Senior Notes 997 — —
Show — breakouts
Long-Term Debt 22,174 — —
Show Long-Term Debt Type breakouts
Notes Payable Other Payables 1,094 — —
Stockholders' Equity
Common Stock (Q) — — —
Show — breakouts
Common Stock 1 1 0.0%
Additional Paid-In Capital (Q) — — —
Show — breakouts
Additional Paid-In Capital 9,305 8,138 +14.3%
Accumulated Other Comprehensive Income (Q) — — —
Show — breakouts
Accumulated Other Comprehensive Income 78 92 -15.2%
Retained Earnings (Q) — — —
Show — breakouts
Retained Earnings 14,131 10,931 +29.3%
Total Stockholders' Equity (Q) — — —
Show — breakouts
Total Stockholders' Equity 23,515 19,162 +22.7%
Minority Interest (Q) — — —
Show — breakouts
Minority Interest -84 -84 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest (Q) — — —
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent 18 38 -52.6%
Accumulated Net Unrealized Investment Gain Loss -3 — —
Accumulated Other Comprehensive Income 78 92 -15.2%
Accumulated Translation Adjustment 64 54 +18.5%
Additional Paid In Capital 9,305 8,138 +14.3%
Common Stock 1 1 0.0%
Noncontrolling Interest -84 -84 0.0%
Retained Earnings 14,131 10,931 +29.3%
Show — breakouts
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 23,431 19,078 +22.8%
Total Liabilities & Equity (Q) — — —
Show — breakouts
Total Liabilities & Equity 56,278 56,434 -0.3%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Depreciation (Q) — — —
Show — breakouts
Depreciation 93 97 -4.1%
Adjustment For Amortization (Q) — — —
Show — breakouts
Adjustment For Amortization 596 599 -0.5%
Stock-Based Compensation (Q) — — —
Show — breakouts
Stock-Based Compensation 218 209 +4.3%
Deferred Income Taxes (Q) — — —
Show — breakouts
Deferred Income Taxes 179 -199 +189.9%
Increase Decrease In Equity Securities Fv Ni (Q) — — —
Show — breakouts
Increase Decrease In Equity Securities Fv Ni -142 426 -133.3%
Other Non-Cash Items (Q) — — —
Show — breakouts
Other Non-Cash Items 183 91 +101.1%
Change in Accounts Receivable (Q) — — —
Show — breakouts
Change in Accounts Receivable 134 79 +69.6%
Change in Inventory (Q) — — —
Show — breakouts
Change in Inventory -52 -223 +76.7%
Change in Prepaid & Other Assets (Q) — — —
Show — breakouts
Change in Prepaid & Other Assets 5 12 -58.3%
Change in Accounts Payable (Q) — — —
Show — breakouts
Change in Accounts Payable -67 -105 +36.2%
Increase Decrease In Income Taxes (Q) — — —
Show — breakouts
Increase Decrease In Income Taxes -29 -552 +94.7%
Increase Decrease In Accrued Liabilities (Q) — — —
Show — breakouts
Increase Decrease In Accrued Liabilities -702 -244 -187.7%
Net Cash from Operations (Q) — — —
Show — breakouts
Net Cash from Operations 2,544 1,757 +44.8%
Investing Activities
Purchases of Investments (Q) — — —
Show — breakouts
Purchases of Investments -525 — —
Proceeds From Sale Of Available For Sale Securities Debt (Q) — — —
Show — breakouts
Proceeds From Sale Of Available For Sale Securities Debt 2,520 — —
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities (Q) — — —
Show — breakouts
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 36 — —
Payments To Acquire Businesses Net Of Cash Acquired (Q) — — —
Show — breakouts
Payments To Acquire Businesses Net Of Cash Acquired -109 -273 +60.1%
Payments To Acquire Other Investments (Q) — — —
Show — breakouts
Payments To Acquire Other Investments -19 -16 -18.8%
Capital Expenditures (Q) — — —
Show — breakouts
Capital Expenditures -117 -104 -12.5%
Other Investing Activities (Q) — — —
Show — breakouts
Other Investing Activities -17 -23 +26.1%
Net Cash from Investing (Q) — — —
Show — breakouts
Net Cash from Investing 1,770 -415 +526.5%
Financing Activities
Proceeds From Issuance Of Common Stock (Q) — — —
Show — breakouts
Proceeds From Issuance Of Common Stock 166 252 -34.1%
Share Repurchases (Q) — — —
Show — breakouts
Share Repurchases -419 -730 +42.6%
Debt Repayments (Q) — — —
Show Debt Instrument breakouts
3.65% Senior Unsecured Notes Due March 2026 · Senior Notes -2.75 — —
Show — breakouts
Debt Repayments -2,766 -1,762 -57.0%
Payments Of Dividends (Q) — — —
Show — breakouts
Payments Of Dividends -1,040 -1,010 -3.0%
Proceeds From Payments For Other Financing Activities (Q) — — —
Show — breakouts
Proceeds From Payments For Other Financing Activities -179 -176 -1.7%
Net Cash from Financing (Q) — — —
Show — breakouts
Net Cash from Financing -4,239 -3,426 -23.7%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) — — —
Show — breakouts
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -11 19 -157.9%
Net Change in Cash (Q) — — —
Show — breakouts
Net Change in Cash 65 -2,065 +103.1%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key